Abstract:A major cause of failure of therapy in patients with non-small cell lung cancer (NSCLC) is development of acquired drug resistance leading to tumor recurrence and disease progression. In addition to the development of new generations of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), different molecular targets may provide opportunities to improve the therapeutic outcomes. In this study, we utilized the core structure 5-fluorouracil (5-FU) or tegafur, a 5-FU prodrug combined through different linkers with resorcinol to generate a series of fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides which inhibit potent Heat Shock Protein 90 (HSP90). These compounds were found to show significant antiproliferative activity in colorectal cancer (CRC) HCT116 and NSCLC A549, H460, and H1975 (EGFR L858R/T790 M double mutation) cells. Compound 12c, developed by molecular docking analysis and enzymatic assays exhibits promising inhibitory activity of HSP90. This compound, 12c shows the most potent HSP90 inhibitory activity with an IC50 value of 27.8 ± 4.4 nM, superior to that of reference compounds AUY-922 (Luminespib) and BIIB021 whose IC50 values are 43.0 ± 0.9 nM and 56.8 ± 4.0 nM respectively. This strong HSP90 inhibitory activity of 12c leads to rapid degradation of client proteins EGFR and Akt in NSCLC cells. In addition, 12c induces significant accumulation of a sub-G1 phase population in parallel with apoptosis by showing activated caspase-3, -8 and -9 and PARP induction. These results provide a new strategy for development of novel HSP90 inhibitors for cancer treatment.

HSP90/LSD1 Dual Inhibitors against Prostate Cancer as well as Patient-Derived Colorectal Organoids

Syntheses of LSD1/HDAC Inhibitors with Demonstrated Efficacy against Colorectal Cancer: In Vitro and In Vivo Studies Including Patient-Derived Organoids

Discovery of Second Generation Heat Shock Protein 110 (HSP110) Inhibitors for Potential Treatment of Colorectal Cancer

Design, Synthesis, and Biological Evaluation of Potent EZH2/LSD1 Dual Inhibitors for Prostate Cancer

Discovery of Novel 5-Cyano-3-phenylindole-Based LSD1/HDAC Dual Inhibitors for Colorectal Cancer Treatment

Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer

Anti-tumor Selectivity of a Novel Tubulin and HSP90 Dual-Targeting Inhibitor in Non-Small Cell Lung Cancer Models.

Discovery of Novel and Potent Dual-Targeting AXL/HDAC2 Inhibitors for Colorectal Cancer Treatment Via Structure-Based Pharmacophore Modelling, Virtual Screening, and Molecular Docking, Molecular Dynamics Simulation Studies, and Biological Evaluation

Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (hsp90) and Cell Division Cycle 37 As Orally Active Inhibitors for the Treatment of Colorectal Cancer.

Design, Synthesis, and Biological Evaluation of Novel Dual Inhibitors of Heat Shock Protein 90/mammalian Target of Rapamycin (hsp90/mtor) Against Bladder Cancer Cells.

Novel Hsp90-Targeting PROTACs: Enhanced synergy with cisplatin in combination therapy of cervical cancer

Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells

Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer

Design, Synthesis, and Structure-Activity Relationship of Novel LSD1 Inhibitors Based on Pyrimidine-Thiourea Hybrids As Potent, Orally Active Antitumor Agents.

Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy

Lipidomic profiling reveals lipid regulation by a novel LSD1 inhibitor treatment

Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment

Identification and biological evaluation of fused tetrahydroisoquinoline derivatives as Wnt/β-catenin signaling inhibitors to suppress colorectal cancer

Discovery of 2 H -Indazole-3-carboxamide Derivatives as Novel Potent Prostanoid EP4 Receptor Antagonists for Colorectal Cancer Immunotherapy.

Synthesis of C3′‐Foused Aryl/Penta‐1,4‐dien‐3‐one/Amine Hybrids as HSP90 C‐Terminal Inhibitors

Design, Synthesis and Biological Evaluation of Novel Dual-Acting Modulators Targeting Both Estrogen Receptor Α (erα) and Lysine-Specific Demethylase 1 (LSD1) for Treatment of Breast Cancer.